The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of the combination of selinexor (SEL), liposomal doxorubicin (DOX) and dexamethasone (Dex) for relapsed and refractory multiple myeloma (RRMM).
 
Rachid C. Baz
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Karos Therapeutics (Inst); Sanofi (Inst)
 
Kenneth H. Shain
Consulting or Advisory Role - Celgene
Speakers' Bureau - Amgen; Celgene; Janssen; Takeda
Research Funding - Celgene (Inst); Signal Genetics (Inst); Verastem (Inst)
 
Melissa Alsina
Speakers' Bureau - Onyx
Research Funding - Takeda (Inst)
 
Jason Brayer
No Relationships to Disclose
 
Tami Rashal
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
Consulting or Advisory Role - Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - Karyopharm Therapeutics
 
Jennifer L Cooksey
No Relationships to Disclose
 
Joel G Turner
No Relationships to Disclose
 
Jana Dawson
No Relationships to Disclose
 
Daniel Sullivan
No Relationships to Disclose